2ⁿᵈ Edition of the Cancer R&D World Conference 2026

Abstract

Cancer rates continue to rise, and treatments become more and more challenging due to resistance mechanisms, undefined targets driving disease and overall lack of clinically relevant systems in which to study the effects of interventions, multimodal modalities, and therapeutics. To address this challenge, Sus Clincials developed an inducible transgenic Oncopig®, a unique genotypically, anatomically, metabolically, and physiologically relevant large animal model that develops inducible site and cell specific tumors for preclinical study of human cancer. The Oncopig® harbors mutations found in the majority of human cancers- KRAS^G12D and TP53^R167H- and results in tumors that mimics the human physiology of cancer.  The Oncopig®  is a more relevant model than the mouse for various reasons, but importantly the size allows utilization of the same interventional tools, such as radiological, imaging and surgical devices all employed in human clinical practice, therefore allowing to understand all aspects of safety, efficacy and metabolim in one model system. The Oncopig® is also an ideal model for investigation but additionally, we have demonstrated the ability to genetically engineer Oncopig® cell lines to facilitate the controlled addition of gene mutations in induced tumors, or add additional comorbities within animal for improved preclinical investigation of the impact of cancer subtypes and defined special populations on diagnostic and therapeutic approaches.  Oncopig® Cancer Model is the only FDA cleared large animal cancer model, that supports device, drug and diagnostic safety, risk and efficacy studies within one animal to help to better facilitate researchers to bring their most promising interventions into the clinic.